Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

about

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

Item

http://www.wikidata.org/entity/Q27727954

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Chemically Linked Vemurafenib ...... FV600E Conformation

@nl

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

@ast

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

@en

type

Item

label

Chemically Linked Vemurafenib ...... FV600E Conformation

@nl

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

@ast

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

@en

prefLabel

Chemically Linked Vemurafenib ...... FV600E Conformation

@nl

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

@ast

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation

@en

P1476

Chemically Linked Vemurafenib ...... V600E Conformation

@en

P2093

Christian Ventocilla

http://www.w3.org/2001/XMLSchema#string

Jasna Maksimoska

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Winkler

http://www.w3.org/2001/XMLSchema#string

Jessie Villanueva

http://www.w3.org/2001/XMLSchema#string

Michael Grasso

http://www.w3.org/2001/XMLSchema#string

Michelle A Estrada

http://www.w3.org/2001/XMLSchema#string

Minu Samanta

http://www.w3.org/2001/XMLSchema#string

P2860

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

MolProbity: all-atom structure validation for macromolecular crystallography

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Processing of X-ray diffraction data collected in oscillation mode

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options

P304

2876-2888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSCHEMBIO.6B00529

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ronen Marmorstein

P577

2016-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27571413

http://www.w3.org/2001/XMLSchema#string

P932

5108658

http://www.w3.org/2001/XMLSchema#string